Tirzepatid 10 mg

Description

Tirzepatide is a research-grade dual incretin agonist supplied in lyophilised form for laboratory use. It acts on both GLP-1 and GIP receptors and has become a central reference compound in metabolic research, especially in models of appetite regulation, body-weight change, glycaemic control and incretin signalling.

Tirzepatide belongs to a newer class of investigational metabolic peptides designed to engage more than one incretin pathway at the same time, rather than targeting GLP-1 alone. This dual-receptor profile makes it especially relevant in research focused on obesity, glucose homeostasis, insulin signalling, energy balance and next-generation metabolic therapeutics. Tirzepatide is supplied as a lyophilised vial for laboratory and analytical use only.

What is Tirzepatide?

Tirzepatide is an investigational dual incretin receptor agonist designed to activate two key receptor systems involved in metabolic regulation:

• GLP-1 receptor
• GIP receptor

This receptor profile places Tirzepatide between Semaglutid a Retatrutid in mechanistic breadth. Semaglutide primarily targets GLP-1 alone, while Retatrutide extends beyond GLP-1/GIP into agonismus glukagonového receptoru. Tirzepatide occupies the middle ground: broader than classical GLP-1 analogues, but more selective than triple agonists.

Because of that positioning, Tirzepatide has become one of the most important benchmark compounds in current metabolic research. It is widely used as a comparison point in studies examining single-, dual- and triple-receptor incretin strategies. Lilly and peer-reviewed clinical literature consistently describe Tirzepatide as a once-weekly dual GIP/GLP-1 receptor agonist with strong effects on glycaemic and body-weight outcomes in human studies.

Why Tirzepatide matters in metabolic research

Tirzepatide is important because it combines GLP-1 signalling with GIP receptor activity, creating a broader incretin profile than GLP-1 agonists alone while remaining more focused than triple agonists such as Retatrutide.

In the literature, Tirzepatide has been studied in relation to:

• regulace tělesné hmotnosti a signalizace chuti k jídlu
• metabolismus glukózy a glykemické markery
• insulin signalling and nutrient handling
• energy balance and systemic metabolic regulation
• comparative incretin research across GLP-1, dual agonist and triple agonist models

For researchers building a metabolic peptide panel, Tirzepatide often serves as the central comparator molecule between Semaglutide and Retatrutide. It is one of the clearest examples of how expanding from a single-pathway GLP-1 agonist to a dual incretin agonist can change the metabolic profile under investigation. Your current page already points in this direction; the difference here is that we’re making the comparison logic and search surface much more explicit.

How Tirzepatide works

Tirzepatide is designed to activate two receptor systems involved in metabolic control.

Aktivita GLP-1 receptoru

Signalizace GLP-1 je spojena se snížením chuti k jídlu, opožděným vyprazdňováním žaludku a podporou inzulínu závislou na glukóze. To je dráha, kterou většina výzkumníků již zná z látek, jako je semaglutid.

Aktivita GIP receptoru

GIP signalling is thought to influence insulin secretion, nutrient handling, adipose metabolism and the overall incretin response to food intake. In dual-agonist research, GIP activity is one of the major reasons Tirzepatide is mechanistically broader than GLP-1-only compounds.

Dual incretin profile

The combination of GLP-1 and GIP activity gives Tirzepatide a different metabolic profile from both Semaglutide and Retatrutide. Compared with Semaglutide, it expands the signalling scope beyond GLP-1 alone. Compared with Retatrutide, it remains more selective because it does not include glucagon receptor agonism.

That makes Tirzepatide particularly useful in research focused on:

• GLP-1 vs dual agonist comparisons
• body-weight and appetite outcomes
• glucose homeostasis and insulin dynamics
• the transition from single-pathway to multi-pathway incretin modulation

Published clinical findings on Tirzepatide

Tirzepatide has become one of the most closely followed metabolic peptides because published human studies have reported substantial effects on body weight, glycaemic control and broader cardiometabolic markers. In the SURMOUNT-1 trial published in the New England Journal of Medicine, once-weekly Tirzepatide produced dose-dependent reductions in body weight over 72 weeks in adults with obesity or overweight, with the highest-dose arm showing some of the strongest weight-loss outcomes reported at the time for an incretin-based therapy.

Tirzepatide has also shown strong glycaemic effects in type 2 diabetes research. In SURPASS-2, Tirzepatide was compared directly with once-weekly Semaglutide and demonstrated greater HbA1c reduction and greater weight reduction across the studied dose arms. Additional SURPASS studies have further established Tirzepatide as one of the key dual agonists in the current metabolic literature. Your current page already cites the most important trials — SURMOUNT-1, SURPASS-2 and related diabetes work — which is exactly the right evidence base for this section.

Taken together, these trials are the main reason Tirzepatide is so often used as a reference point in modern obesity and diabetes research. It sits at the centre of the comparison between GLP-1 agonists, dual GLP-1/GIP agonists, and newer triple agonist approaches.

Publikované výsledky týkající se bezpečnosti a snášenlivosti

Published clinical studies on Tirzepatide indicate that the most commonly reported adverse events are gastrointestinal, especially nausea, diarrhoea, decreased appetite, vomiting and constipation. As with other incretin-based agents, these events were generally more common than with placebo and were often dávkově závislý, particularly during the dose-escalation phase of treatment.

Across the major clinical programs, most gastrointestinal events were described as mírný až střední in severity, and discontinuation rates were still an important part of how Tirzepatide’s overall profile was evaluated. This is one of the reasons published Tirzepatide research is typically discussed not only in terms of efficacy, but also in terms of snášenlivost během eskalace, GI event burden and the balance between metabolic benefit and dropout risk.

This section summarises published findings on investigational and clinical Tirzepatide research, not instructions or expectations for use of this product.

Published dosing schedules used in Tirzepatide research

Published Tirzepatide studies generally used once-weekly administration with stepwise dose escalation rather than starting at the final target dose immediately. In the major obesity and diabetes trials, Tirzepatide was typically studied at 5 mg, 10 mg and 15 mg maintenance doses, with escalation from a lower starting dose over a period of weeks to improve tolerability. Your current reference list already points to the core trials that established this structure.

In practical terms, the published research design for Tirzepatide is important because it shows that efficacy and tolerability were studied together. Researchers did not simply test “one Tirzepatide dose”; they tested staged escalation strategies leading to different maintenance doses. That is one of the reasons Tirzepatide remains such a useful comparator compound in metabolic peptide research.

Example of the maintenance-dose structure commonly used in major trials

Tyto rozvrhy jsou zahrnuty jako souhrn publikovaného návrhu výzkumu a nejsou pokyny k použití tohoto produktu.

Tirzepatide vs Semaglutide vs Retatrutide

Researchers often compare these three compounds because they sit on the same metabolic spectrum, but they are not interchangeable.

Tirzepatid

• Duální agonistaGLP-1 + GIP
• Central benchmark for dual incretin research
• Často diskutováno v souvislosti s body-weight outcomes, glycaemic control and incretin signalling

Semaglutid

• Jediný agonistaGLP-1
• More selective and mechanistically narrower
• Společný referenční bod pro Výzkum dráhy GLP-1

Retatrutid

• Trojitý agonistaGLP-1 + GIP + glukagon
• Broader receptor profile than Tirzepatide
• Často diskutováno v souvislosti s weight loss, energy expenditure and next-generation multi-pathway metabolic modulation

For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs.

Vlastnosti produktu

Aplikace: laboratorní a analytický výzkum
Použití omezené: není určeno k lidské spotřebě; pro lékařské, veterinární ani kosmetické použití
Vyrobeno v zařízeních splňujících správnou výrobní praxi (GMP) za přísných protokolů kontroly kvality.
Každá šarže je po výrobě pečlivě laboratorně testována (Certifikát o analýze najdete pod obrázky produktů).
Lyofilizováno (sušeno mrazem) pro maximální stabilitu a prodlouženou trvanlivost.
Uzavřeno ve sterilních lahvičkách, připraveno k rekonstituci.
Purity: ≥99% (HPLC-tested)
Appearance: Lyophilized white/off-white powder
Molekulární vzorec: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight: 4813.45
Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
ÚložištěNeotevřené lyofilizované lahvičky jsou nejlépe skladovány chlazené při 2–8 °C, což je metoda skladování potvrzená naším výrobním partnerem a vhodná až po dobu 24 měsíců. Preferuje se chlazení, protože minimalizuje zbytečné cykly zmrazování a rozmrazování během běžné manipulace. Pokud je vyžadováno podstatně delší skladování, lze zmrazené uchovávat i neotevřené lyofilizované lahvičky. Po rekonstituci vždy skladujte při 2–8 °C a nezmrazujte.

Nezávislé ověření třetí stranou

Tato šarže prošla dodatečným analytickým ověřením třetí stranou prostřednictvím společnosti Janoshik Analytical
Batch: TR10-260423
Internal HPLC purity: 99.13%
Third-party verification: 99.62% independently confirmed high purity and identity consistency. Zobrazit ověření třetí stranou.

Rekonstituce a manipulace

Tirzepatide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with bakteriostatická voda před použitím. Peptidy třídy GLP-1 se někdy rozpouštějí pomalu a vyžadují velmi jemné rozpouštění, aby se zabránilo pěnění nebo vzniku mírného zákalu.

Pro další pokyny k výběru rozpouštědla, plánování koncentrací a skladování viz úplné Průvodce rekonstitucí peptidů a Kalkulačka rekonstituce.

Vybrané výzkumné reference

• Jastreboff AM a kol. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022.
• Frias JP et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine, 2021.
• Ludvik B et al. “Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin.” The Lancet, 2021.
• Coskun T a kol. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.” Molecular Metabolism, 2018.

Často kladené dotazy

What kind of peptide is Tirzepatide?

Tirzepatide is an investigational dual incretin agonist designed to activate GLP-1 and GIP receptors.

How is Tirzepatide different from Semaglutide?

Semaglutide primarily targets GLP-1 alone, while Tirzepatide combines GLP-1 and GIP receptor activity, giving it a broader incretin signalling profile.

How is Tirzepatide different from Retatrutide?

Retatrutide is a triple agonist that adds glucagon receptor activity to the GLP-1/GIP profile. Tirzepatide remains more selective as a dual GLP-1/GIP agonist.

What research areas is Tirzepatide associated with?

Tirzepatide has been studied in the literature in relation to body-weight outcomes, appetite regulation, glycaemic control, insulin signalling and incretin biology.

Je tento produkt určen k lidskému použití?

Ne. Tento produkt je dodáván výhradně pro výzkumné účely a není určen k lidské spotřebě ani k terapeutickému použití.

Související výzkumný kontext

Tirzepatide is part of the dual incretin receptor agonist (GLP-1/GIP) metabolic research class. For mechanistic comparison with single-pathway GLP-1 agonists and triple-agonist compounds, see our Průvodce výzkumem metabolismu GLP-1.

Procházet všechny sloučeniny v Kategorie metabolického výzkumu.

Výzkumníci porovnávající aktivaci více receptorů mohou také zkoumat:

• Retatrutide (GLP-1/GIP/glucagon triple-receptor agonist)
• Semaglutid (agonista receptoru GLP-1)

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer:
Tento produkt je prodáván pouze pro výzkumné účely. Není určen k diagnostice, léčbě, vyléčení nebo prevenci jakýchkoli onemocnění. Kupující přebírá plnou odpovědnost za řádnou manipulaci a použití.